ONCOmmunity

Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.

By: Satoshi Muto, Hironori Takagi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki

Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan smutoo@fmu.ac.jp.
2017-04-19; doi: 10.21873/anticanres.11676

Abstract

Background/aim

Reportedly, hypertension tends to be associated with response to bevacizumab therapy, because bevacizumab suppresses vascular nitric oxide production. In this study we examined the predictive value of nitric oxide in bevacizumab-treated non-small cell lung cancer (NSCLC) patients.

Patients

Fifteen patients with advanced or recurrent NSCLC treated with bevacizumab-based regimens were evaluated retrospectively. Serum NOx (NO2(-)/NO3(-)) was assayed by the Griess method.

Results

Serum nitric oxide levels were decreased after two courses of bevacizumab treatment in our responder group (p=0.02). According to the change in nitric oxide levels after the second course of treatment, median progression-free survival was 11.0 months in the group with decreased serum nitric oxide and 7.6 months in the group with increased serum nitric oxide (p=0.08).

Conclusion

Serum nitric oxide levels could be a predictive biomarker for response to bevacizumab in NSCLC patients.